ARTICLE | Company News
Go Therapeutics Inc. (Cambridge, Mass.) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to develop and commercialize a glycotargeting bispecific antibody developed using Go Therapeutics’s platform for $9 million in an upfront payment and near-term milestones. The biotech is eligible for up to $186 million in additional milestones, plus mid single-digit to low double-digit royalties.
Cancer cells have long been known to harbor proteins differently glycosylated from those in normal cells, but the difficulty has been in developing high-affinity therapies that target individual sugars specifically (see “Sweet Specificity”)...